キタムラ　マユミ   KITAMURA MAYUMI   北村　真由美    所属   朝日大学  保健医療学部看護学科 小児看護学    職種   助教
言語種別	英語
発行・発表の年月	2023/10
形態種別	速報，短報，研究ノート等（学術雑誌）
査読	査読あり
標題	Analysis of spontaneous adverse events with Janus kinase inhibitors reported to the Japanese Adverse Drug Event Report database
執筆形態	共著
掲載誌名	Pharmaceutical and Biomedical Research
掲載区分	国内
出版社・発行元	Pharmaceutical and Biomedical Research
著者・共著者	Hideyuki Tanaka, Mika Maezawa,Satoshi Nakao, Koumi Miyasaka, Sakiko Hirofuji,Moe Yamashita, Kensuke Matsui, Nanaka Ichihara, Yuka Nokura, Mari Iwata, Mayumi Kitamura, Megumi Horibe, Hirofumi Tamaki, Kazuhiro Iguchi, Mitsuhiro Nakamura
概要	Adjusted reported odds ratios (ROR) were used to assess disproportionality in the pharmacovigilance data and time-to-onset analysis was performed using Weibull shape parameters.The JADER database contained 823662 reports published between April 2004 and March 2023. Pneumonia and herpes zoster were associated with all JAK inhibitors except filgotinib. Adjusted RORs for pneumonia with peficitinib, tofacitinib, baricitinib, ruxolitinib, filgotinib, and upadacitinib were 4.40 (95% confidence interval: 3.36–5.75), 6.93 (6.18–7.77), 6.51 (5.52–7.67), 3.30 (2.76–3.95), 4.39 (2.55–7.58), and 6.11 (4.53–8.23), respectively. Adjusted RORs for herpes zoster with peficitinib, tofacitinib, baricitinib, ruxolitinib, and upadacitinib were 8.94 (5.69–14.05), 31.82 (27.58–36.71), 34.96 (28.92–42.26), 5.24 (3.57–7.70), and 33.19 (23.81–46.27), respectively. The median time-to-onset of pneumonia and HZ with JAK inhibitor usage ranged from 2 to 6 months and 4 to 7 months, respectively.